Alumis Inc (ALMS) Stock Forecast & Price Target

Alumis is backed by promising phase II and III data for its TYK2 inhibitors, specifically envudeucitinib and A-005, offering potential therapeutic benefits for psoriasis (PsO) and systemic lupus erythematosus (SLE). Despite potential competitive pressures from other oral therapies, Alumis' envudeucitinib remains relevant and comparable to its main competitor, zasocitinib, on efficacy. Additionally, the company's other internal programs, including SGT-003 for Duchenne muscular dystrophy, hold promising market potential and could increase shareholder value. However, there are risks to achieving the projected price objective, including delays in commercialization and competitive pressures in the market, which could result in equity dilution for shareholders.

Alumis is a clinical-stage biopharmaceutical company, focusing primarily on developing two TYK2 inhibitors for immune-mediated diseases. While the company has promising phase II and III data for its candidates in certain indications, it faces commercial disadvantages such as a BID dosing schedule and stiff competition from other oral therapies. Additionally, regulatory risks and the need for the right partner to successfully commercialize envu add to the negative outlook for the company's stock. The financials and key data metrics from collaboration revenue and net cash to projected peak sales and NPV/share also do not support a positive forecast for Alumis's stock.